» Articles » PMID: 1783440

Pharmacological Properties of Cephalosporins

Overview
Journal Infection
Date 1991 Jan 1
PMID 1783440
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The cephalosporins differ in the substituents attached at the 3 and/or 7 positions of the molecule. Very schematically, substitution at C3 mainly modifies the overall pharmacokinetic properties whereas substitution at position 7 influences the antibacterial characteristics. When using the more common "generation" system for classification, three generations can be distinguished on the basis of their antibacterial spectrum, potency, and their stability to beta-lactamases. The first generation cephalosporins have similar antibacterial and pharmacokinetic characteristics. C3-esterified cephalosporins (e.g. cephalothin and cephapirin) are significantly metabolized. The so-called second generation cephalosporins exhibit only minor differences with respect to the pharmacokinetic properties in contrast to the third generation cephalosporins. The apparent volumes of distribution of most cephalosporins range between seven and 20 1, indicating that they mainly stay in the extracellular space. Plasma protein binding is variable from compound to compound. Generally, the major route of elimination of most cephalosporins is via the kidney except for cefoperazone and ceftriaxone which are both excreted to a large extent by the biliary route. With the exception of cefonicid, cefotetan and cefriaxone, which have longer elimination half-lives (i.e. 4.5, 3.5 and around eight hours), all other cephalosporins have a half-life ranging from 0.5 to 2.5 hours. The pattern of adverse reactions is comparable for all the cephalosporins although there are slight differences in both the incidence and the type of reactions. The major categories of adverse reactions are gastrointestinal, dermatologic, hypersensitivity, haematologic, hepatic, renal as well as CNS effects. Alcohol intolerance (antabus-like effect) can occur when cephalosporins containing the NMTT moiety are administered concomitantly.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Systemic antibiotic prophylaxis in arthroplasty - a narrative review of how many doses are optimal.

Wahl P, Drennan P, Schlappi M, Achermann Y, Leunig M, Gautier E EFORT Open Rev. 2024; 9(12):1106-1119.

PMID: 39620563 PMC: 11619733. DOI: 10.1530/EOR-24-0022.


Cephalotin Versus Dicloxacillin for the Treatment of Methicillin-Susceptible Bacteraemia: A Retrospective Cohort Study.

Quinonez-Flores A, Martinez-Guerra B, Roman-Montes C, Tamez-Torres K, Gonzalez-Lara M, Ponce-de-Leon A Antibiotics (Basel). 2024; 13(2).

PMID: 38391562 PMC: 10885996. DOI: 10.3390/antibiotics13020176.


Complex-Forming Properties of Ceftazidime with Fe(III) Ions in an Aqueous Solution.

Pajak M, Wozniczka M, Fichna J Molecules. 2022; 27(21).

PMID: 36364052 PMC: 9653668. DOI: 10.3390/molecules27217226.


Prevalence and clinical characteristics of antibiotics associated drug induced liver injury.

Park J, Hong S, Won Jun D, Yoon J, Lee K, Lee H Ann Transl Med. 2021; 9(8):642.

PMID: 33987340 PMC: 8106034. DOI: 10.21037/atm-20-5144.


Is There a Difference in Infection Risk Between Single and Multiple Doses of Prophylactic Antibiotics? A Meta-analysis.

Ryan S, Kildow B, Tan T, Parvizi J, Bolognesi M, Seyler T Clin Orthop Relat Res. 2019; 477(7):1577-1590.

PMID: 30811357 PMC: 6999965. DOI: 10.1097/CORR.0000000000000619.


References
1.
Ward A, Richards D . Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985; 30(5):382-426. DOI: 10.2165/00003495-198530050-00002. View

2.
Neu H . Third generation cephalosporins: safety profiles after 10 years of clinical use. J Clin Pharmacol. 1990; 30(5):396-403. DOI: 10.1002/j.1552-4604.1990.tb03476.x. View

3.
Tune B, Fravert D, Hsu C . Oxidative and mitochondrial toxic effects of cephalosporin antibiotics in the kidney. A comparative study of cephaloridine and cephaloglycin. Biochem Pharmacol. 1989; 38(5):795-802. DOI: 10.1016/0006-2952(89)90233-5. View

4.
Bergan T . Comparative pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration. Chemotherapy. 1977; 23(6):389-404. DOI: 10.1159/000222009. View

5.
Foord R . Cephaloridine, cephalothin and the kidney. J Antimicrob Chemother. 1975; 1(3 Suppl):119-33. DOI: 10.1093/jac/1.suppl_3.119. View